Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world
- PMID: 34253291
- PMCID: PMC8277373
- DOI: 10.7554/eLife.67635
Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world
- PMID: 34253291
- PMCID: PMC8277373
- DOI: 10.7554/eLife.67635
Abstract
Background: Vaccination is one of the most effective public health interventions. We investigate the impact of vaccination activities for Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae, and yellow fever over the years 2000-2030 across 112 countries.
Methods: Twenty-one mathematical models estimated disease burden using standardised demographic and immunisation data. Impact was attributed to the year of vaccination through vaccine-activity-stratified impact ratios.
Results: We estimate 97 (95%CrI[80, 120]) million deaths would be averted due to vaccination activities over 2000-2030, with 50 (95%CrI[41, 62]) million deaths averted by activities between 2000 and 2019. For children under-5 born between 2000 and 2030, we estimate 52 (95%CrI[41, 69]) million more deaths would occur over their lifetimes without vaccination against these diseases.
Conclusions: This study represents the largest assessment of vaccine impact before COVID-19-related disruptions and provides motivation for sustaining and improving global vaccination coverage in the future.
Funding: VIMC is jointly funded by Gavi, the Vaccine Alliance, and the Bill and Melinda Gates Foundation (BMGF) (BMGF grant number: OPP1157270 / INV-009125). Funding from Gavi is channelled via VIMC to the Consortium's modelling groups (VIMC-funded institutions represented in this paper: Imperial College London, London School of Hygiene and Tropical Medicine, Oxford University Clinical Research Unit, Public Health England, Johns Hopkins University, The Pennsylvania State University, Center for Disease Analysis Foundation, Kaiser Permanente Washington, University of Cambridge, University of Notre Dame, Harvard University, Conservatoire National des Arts et Métiers, Emory University, National University of Singapore). Funding from BMGF was used for salaries of the Consortium secretariat (authors represented here: TBH, MJ, XL, SE-L, JT, KW, NMF, KAMG); and channelled via VIMC for travel and subsistence costs of all Consortium members (all authors). We also acknowledge funding from the UK Medical Research Council and Department for International Development, which supported aspects of VIMC's work (MRC grant number: MR/R015600/1).JHH acknowledges funding from National Science Foundation Graduate Research Fellowship; Richard and Peggy Notebaert Premier Fellowship from the University of Notre Dame. BAL acknowledges funding from NIH/NIGMS (grant number R01 GM124280) and NIH/NIAID (grant number R01 AI112970). The Lives Saved Tool (LiST) receives funding support from the Bill and Melinda Gates Foundation.This paper was compiled by all coauthors, including two coauthors from Gavi. Other funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Keywords: LMICs; epidemiology; global health; mathematical modelling; vaccine impact; virus.
© 2021, Toor et al.
Conflict of interest statement
JT, SE, XL, KA, EC, HC, AC, Md, KE, MF, IG, TH, WH, DH, JH, KJ, AK, PK, AK, JL, XL, TM, CM, SM, SN, TP, AP, DR, SR, CS, SS, YT, HT, QT, ST, EV, NW, AW, KW, NF, KG No competing interests declared, MJ MLJ has received research funding from Sanofi Pasteur unrelated to the present work, MJ Reviewing editor, eLife, BL BAL reports grants and personal fees from Takeda Pharmaceuticals, personal fees from World Health Organization, outside the submitted work, TP TAP receives support from Emergent Biosolutions for work unrelated to his contribution to this study, HR HR is an employee of Center for Disease Analysis Foundation which has received grants from Gilead Sciences, AbbVie, Zeshan Foundation and EndHep2030 fund for projects unrelated to this work; HBV epidemiology data was funded by a grant from John Martin Foundation (Grant number 24), CT CLT received a consulting payment from GSK in 2018 (outside the submitted work)
Figures
Figure 1.. Mean predicted deaths due to…
Figure 1.. Mean predicted deaths due to the 10 Vaccine Impact Modelling Consortium (VIMC) pathogens…
Figure 2.. Deaths averted per year of…
Figure 2.. Deaths averted per year of vaccination for hepatitis B (HepB), Haemophilus influenzae type…
Appendix 5—figure 1.. Deaths averted per calendar…
Appendix 5—figure 1.. Deaths averted per calendar year for hepatitis B (HepB), Haemophilus influenzae type…
Appendix 5—figure 2.. Deaths averted per birth…
Appendix 5—figure 2.. Deaths averted per birth cohort year for hepatitis B (HepB), Haemophilus influenzae …
Appendix 5—figure 3.. Comparison of fully vaccinated…
Appendix 5—figure 3.. Comparison of fully vaccinated persons (FVPs) in millions between 2017 and 2019…
Appendix 5—figure 4.. Estimated number of deaths…
Appendix 5—figure 4.. Estimated number of deaths averted per year of vaccination in 2000, 2019,…
Appendix 5—figure 5.. Mean predicted deaths for…
Appendix 5—figure 5.. Mean predicted deaths for children under-5 with and without vaccination due to…
Appendix 5—figure 6.. Global deaths for hepatitis…
Appendix 5—figure 6.. Global deaths for hepatitis B per calendar year (in thousands) for all…
Appendix 5—figure 7.. Deaths for hepatitis B…
Appendix 5—figure 7.. Deaths for hepatitis B in the PINE countries (Pakistan - PAK, India…
Appendix 5—figure 8.. Global deaths for measles…
Appendix 5—figure 8.. Global deaths for measles per calendar year (in thousands) for all ages…
Appendix 5—figure 9.. Deaths for measles in…
Appendix 5—figure 9.. Deaths for measles in the PINE countries (Pakistan - PAK, India -…
Appendix 5—figure 10.. Global deaths for yellow…
Appendix 5—figure 10.. Global deaths for yellow fever per calendar year (in thousands) for all…
Appendix 5—figure 11.. Deaths for yellow fever…
Appendix 5—figure 11.. Deaths for yellow fever in Nigeria - NGA and Ethiopia - ETH…
Appendix 5—figure 12.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 12.. Fully vaccinated persons (FVPs) per vaccination target population for Hepatitis B for…
Appendix 5—figure 13.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 13.. Fully vaccinated persons (FVPs) per vaccination target population for Haemophilus influenzae type…
Appendix 5—figure 14.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 14.. Fully vaccinated persons (FVPs) per vaccination target population for measles for years…
Appendix 5—figure 15.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 15.. Fully vaccinated persons (FVPs) per vaccination target population for Streptococcus pneumoniae (PCV)…
Appendix 5—figure 16.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 16.. Fully vaccinated persons (FVPs) per vaccination target population for rotavirus for years…
Appendix 5—figure 17.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 17.. Fully vaccinated persons (FVPs) per vaccination target population for human papillomavirus (HPV)…
Appendix 5—figure 18.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 18.. Fully vaccinated persons (FVPs) per vaccination target population for rubella for years…
Appendix 5—figure 19.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 19.. Fully vaccinated persons (FVPs) per vaccination target population for yellow fever (YF)…
Appendix 5—figure 20.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 20.. Fully vaccinated persons (FVPs) per vaccination target population for Neisseria meningitidis serogroup…
Appendix 5—figure 21.. Fully vaccinated persons (FVPs)…
Appendix 5—figure 21.. Fully vaccinated persons (FVPs) per vaccination target population for Japanese encephalitis (JE)…
Appendix 5—figure 22.. Deaths averted per 100,000…
Appendix 5—figure 22.. Deaths averted per 100,000 population per year of vaccination for hepatitis B…
References
-
- Abbas K, Procter SR, van Zandvoort K, Clark A, Funk S, Mengistu T, Hogan D, Dansereau E, Jit M, Flasche S, LSHTM CMMID COVID-19 Working Group Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. The Lancet Global Health. 2020a;8:e1264–e1272. doi: 10.1016/S2214-109X(20)30308-9. - DOI - PMC - PubMed
-
- Abbas KM, van Zandvoort K, Brisson M, Jit M. Effects of updated demography, disability weights, and cervical Cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. The Lancet Global Health. 2020b;8:e536–e544. doi: 10.1016/S2214-109X(20)30022-X. - DOI - PMC - PubMed
-
- Abbas K, Hadley L. Prime. swh:1:rev:0da13630968de0863f38294a1c234c5947baf97eSoftware Heritage. 2021 https://archive.softwareheritage.org/swh:1:rev:0da13630968de0863f38294a1...
-
- Amouzou A, Richard SA, Friberg IK, Bryce J, Baqui AH, El Arifeen S, Walker N. How well does LiST capture mortality by wealth quintile? A comparison of measured versus modelled mortality rates among children under-five in Bangladesh. International Journal of Epidemiology. 2010;39:i186–i192. doi: 10.1093/ije/dyq034. - DOI - PMC - PubMed
-
- Anderson RM, May RM. Infectious Disease of Humans: Dynamics and Control. Oxford Univerity Press; 1991.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
